Patient characteristics
| Characteristic . | Patients aged 65-69 y . | Patients aged 70-74 y . | Patients aged ≥75 y . | All patients . | ||||
|---|---|---|---|---|---|---|---|---|
| (n = 202) . | (n = 176) . | (n = 173) . | (n = 551) . | |||||
| Age, median (range), y | 67 | (65-69) | 72 | (70-74) | 78.6 | (75-90) | 72.2 | (65-90) |
| Urban/suburban, n (%) | 160 | (79.2) | 142 | (80.7) | 142 | (82.1) | 444 | (80.5) |
| Male sex, n (%) | 108 | (53.5) | 93 | (52.8) | 98 | (56.6) | 299 | (54.3) |
| Baseline Charlson Comorbidity Index, mean (SD)∗ | 5 | (3.2) | 5 | (3.3) | 5 | (3.3) | 5 | (3.24) |
| Median (range) | 4 | (0-15) | 4 | (0-15) | 4 | (0-15) | 4 | (0-15) |
| Bridging therapies, n (%)† | ||||||||
| Any therapy | 102 | (50.5) | 69 | (39.2) | 91 | (52.6) | 262 | (47.5) |
| Chemotherapy or targeted therapy | 64 | (31.7) | 41 | (23.3) | 55 | (31.8) | 160 | (29.0) |
| Corticosteroids | <50 | (∼) | <50 | (∼) | 23 | (13.3) | 73 | (27.9) |
| Radiotherapy | <11 | (∼)‡ | <11 | (∼)‡ | 13 | (7.5) | 29 | (11.1) |
| CAR T-cell administration setting, n (%) | ||||||||
| Inpatient | 171 | (84.6) | 155 | (88.1) | 130 | (75.1) | 456 | (82.8) |
| Length of stay, mean (SD), d | 19.7 | (12.36) | 24.2 | (21.15) | 20.5 | (13.09) | 21.4 | (16.2) |
| Outpatient | 31 | (15.3) | 21 | (11.9) | 43 | (24.9) | 95 | (17.2) |
| Characteristic . | Patients aged 65-69 y . | Patients aged 70-74 y . | Patients aged ≥75 y . | All patients . | ||||
|---|---|---|---|---|---|---|---|---|
| (n = 202) . | (n = 176) . | (n = 173) . | (n = 551) . | |||||
| Age, median (range), y | 67 | (65-69) | 72 | (70-74) | 78.6 | (75-90) | 72.2 | (65-90) |
| Urban/suburban, n (%) | 160 | (79.2) | 142 | (80.7) | 142 | (82.1) | 444 | (80.5) |
| Male sex, n (%) | 108 | (53.5) | 93 | (52.8) | 98 | (56.6) | 299 | (54.3) |
| Baseline Charlson Comorbidity Index, mean (SD)∗ | 5 | (3.2) | 5 | (3.3) | 5 | (3.3) | 5 | (3.24) |
| Median (range) | 4 | (0-15) | 4 | (0-15) | 4 | (0-15) | 4 | (0-15) |
| Bridging therapies, n (%)† | ||||||||
| Any therapy | 102 | (50.5) | 69 | (39.2) | 91 | (52.6) | 262 | (47.5) |
| Chemotherapy or targeted therapy | 64 | (31.7) | 41 | (23.3) | 55 | (31.8) | 160 | (29.0) |
| Corticosteroids | <50 | (∼) | <50 | (∼) | 23 | (13.3) | 73 | (27.9) |
| Radiotherapy | <11 | (∼)‡ | <11 | (∼)‡ | 13 | (7.5) | 29 | (11.1) |
| CAR T-cell administration setting, n (%) | ||||||||
| Inpatient | 171 | (84.6) | 155 | (88.1) | 130 | (75.1) | 456 | (82.8) |
| Length of stay, mean (SD), d | 19.7 | (12.36) | 24.2 | (21.15) | 20.5 | (13.09) | 21.4 | (16.2) |
| Outpatient | 31 | (15.3) | 21 | (11.9) | 43 | (24.9) | 95 | (17.2) |
∼, value withheld to comply with the CMS policy of minimizing the risk to identify patients.
Total 516 patients are included in baseline Charlson Comorbidity Index calculation.
Presence of therapy in the 28-day period before CAR T-cell treatment, excluding therapies administered on the same day as CAR T-cell therapy. Cyclophosphamide and fludarabine administered in the period 10 days before CAR T-cell therapy are also excluded.
The Centers for Medicare & Medicaid Services (CMS) cell size suppression policy sets minimum thresholds for the display of CMS data, in which no cell (eg, admissions, discharges, patients, and services) containing a value of 1 to 10 can be reported directly.